Azora Therapeutics
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Azora Therapeutics is a biopharmaceutical company developing treatments for serious inflammatory diseases. Its lead program, AT177, is an oral, colon-targeted aryl hydrocarbon receptor agonist in deve...
Latest News
4 days ago · globenewswire.com
Azora Therapeutics Reports 2026 Third Quarter Financial Results and Provides Business UpdateAzora Therapeutics commenced trading on Nasdaq as “AZR” New executive team and Board of Directors appointed AT177 IND submission and Phase 1a initiation on track for the first half of 2027 LOS ANGELES, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Azora Therapeutics, Inc. (Nasdaq: AZR) (“Azora” or the “Company”), a biopharmaceutical company developing locally acting treatments for serious immune-mediated and inflammatory diseases, today provided a business update and reported its financial results for the third quarter ended September 30, 2026. During the quarter, Azora continued to advance AT177 through IND-enabling studies and expanded its scientific and operating team.
12 days ago · globenewswire.com
Azora Therapeutics Appoints Board of Directors with Extensive Drug Development and Inflammatory Bowel Disease ExpertiseLOS ANGELES, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Azora Therapeutics, Inc. (Nasdaq: AZR), a biopharmaceutical company developing treatments for serious inflammatory diseases, today announced it has established a five-member board of directors with deep drug development experience, a track record of FDA approvals, expertise in public-company governance, and clinical capabilities in gastroenterology and immunology. “The depth and diversity of expertise represented in our board of directors position Azora for success in advancing AT177 into the clinic and through proof of concept as we aim to restore intestinal health for people living with ulcerative colitis,” said Matt Davidson, Ph.D.
Add to Watchlist
Select watchlists to add or remove AZR